InflaRx NV (IFRX)
1.60
+0.07
(+4.58%)
USD |
NASDAQ |
Oct 09, 16:00
1.59
-0.01
(-0.62%)
After-Hours: 20:00
InflaRx Cash from Operations (Quarterly) : -2.937M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.937M |
| March 31, 2026 | -8.648M |
| September 30, 2025 | -11.32M |
| June 30, 2025 | -9.696M |
| March 31, 2025 | -14.75M |
| September 30, 2024 | -11.21M |
| June 30, 2024 | -12.93M |
| March 31, 2024 | -16.14M |
| December 31, 2023 | -11.36M |
| September 30, 2023 | -5.702M |
| June 30, 2023 | -12.32M |
| March 31, 2023 | -11.28M |
| December 31, 2022 | -5.702M |
| September 30, 2022 | -1.729M |
| June 30, 2022 | -12.56M |
| March 31, 2022 | -14.43M |
| December 31, 2021 | -12.39M |
| Date | Value |
|---|---|
| September 30, 2021 | -11.25M |
| June 30, 2021 | -9.465M |
| March 31, 2021 | -12.54M |
| December 31, 2020 | -12.22M |
| September 30, 2020 | -11.26M |
| June 30, 2020 | -8.477M |
| March 31, 2020 | -11.59M |
| December 31, 2019 | -17.82M |
| September 30, 2019 | -8.969M |
| June 30, 2019 | -11.40M |
| March 31, 2019 | -9.649M |
| December 31, 2018 | -9.337M |
| September 30, 2018 | -4.444M |
| June 30, 2018 | -6.208M |
| March 31, 2018 | -7.068M |
| December 31, 2017 | -4.410M |
| September 30, 2017 | -4.134M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 12.56M |
| Immatics NV | -70.00M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 14.90M |
| Cash from Financing (Quarterly) | 138.70M |
| Free Cash Flow | -32.78M |
| Free Cash Flow Per Share (Quarterly) | -0.0253 |
| Free Cash Flow to Equity (Quarterly) | -2.984M |
| Free Cash Flow to Firm (Quarterly) | -2.962M |
| Free Cash Flow Yield | -25.18% |